Introduction
Vogt-Koyanagi-Harada (VKH) disease is a T-cell mediated multisystemic autoimmune inflammatory disorder characterized by skin, ocular, auditory and neurologic involvement. The T-cell mediated granulomatous intraocular inflammation is responsible for vitritis, disk edema, serous retinal detachments, and eventual sunset glow fundus.1T-cells target melanocytes, with an ensuing cascade leading to four distinct disease phases as follows: prodromal, uveitis, convalescent, and recurrent.2 VKH symptoms include headache, meningismus, hearing loss, poliosis, alopecia, and vitiligo.3 It is most prevalent in Asians, Native Americans, Hispanics, and Middle Easterners. If promptly and adequately treated, patients can experience good outcomes and avoid complications including sunset glow fundus, cataracts, glaucoma, subretinal fibrosis, and choroidal neovascularization. Some studies have reported the link between some viral infections such as cytomegalovirus (CMV) and Epstein Barr virus (EBV) and the development of VKH. It has been postulated that similarity between peptides on melanocytes and some exogenous viral peptides lead to adverse T-cells attacks on melanocytes-containing tissues and lead to the symptoms seen in VKH.4 We report a case of a VKH syndrome in a patient diagnosed with COVID-19.